Description: Bexarotene (LGD1069) is a retinoid analogue that is used to treat the skin manifestations of cutaneous T cell lymphoma (CTCL). Target: Retinoid Receptor, Autophagy. Smiles: CC1(C)C=2C(C(C)(C)CC1)=CC(C)=C(C(=C)C3=CC=C(C(O)=O)C=C3)C2. References: Zhang C, et al. Clin Cancer Res, 2002, 8(5), 1234-1240.

Bexarotene is an agonist of retinoid X receptors (RXRs, EC50s = 28, 25, and 20 nM for RXRalpha, RXRbeta, and RXRgamma, respectively, in reporter assays). It is selective for RXRs over retinoic acid receptors (RARs, EC50s = >10 µM for RARalpha, RARbeta, and RARgamma). Bexarotene (10 µM) induces apoptosis in MJ, HuT...

Bexarotene is an oral antineoplastic agent used for cutaneous T cell lymphoma. Researchers have discovered that bexarotene reduced amyloid plaque and that could be used to treat Alzheimer's symptoms.

Bexarotene (LGD-1069) is a synthetic retinoid analog with specific affinity for the retinoid X receptor and belongs to a group of compounds called rexinoids. It is an oral, noncytotoxic drug that was approved in Europe and in the U.S.A. for the treatment of refractory advanced-stage cutaneous T-cell lymphomas...